Alphabet subsidiary GV was part of a consortium in a round that will fund the progress of the precision medicine developer's lead drug candidate into the clinic.
US-based precision medicine developer Monte Rosa Therapeutics has secured $95m in a series C round that included GV, a corporate venturing unit for internet technology group Alphabet, and investment and financial services group Fidelity.
Life sciences investment firm Avoro Capital Advisors led the round, which also featured RTW Investments, funds and accounts managed by BlackRock and funds and accounts advised by T Rowe Price Associates.
The new investors were joined by existing backers including Versant Ventures, New Enterprise Associates (NEA),…
